Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q2 FY2026 research & development of $19.44M fell 30.7% year over year, behind the -20.8% change in trailing-twelve-month research & development. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • Research & development amounted to 163.4% of revenue in FY2025, down 31.0 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.7% toward the trailing-twelve-month pace of -20.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.44M-6.8% QoQ
Last fiscal yearSep 2025
$106.74M-18.8% YoY
LTMMar 2026
$91.32M-20.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.7%——
1 year-18.8%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
106.74M USD
Year-over-year change
-18.8%
4-year CAGR
-11.5%

Research & Development vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 research & development of $91.32M is the 5th highest of the 11 companies compared; the peer median is $80.59M.
  • Its year-over-year change of -20.8% is the 8th highest of 11, against a peer median of -6.2%.
  • Research & development amounts to 131.9% of revenue for ENTA, versus a peer median of 473.0%.
ENTA Competitors Peer median
Research & Development for ENTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M -24.6%-10.1%27721.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M -12.6%+4.1%—
Peer median (excluding ENTA) $80.59M-6.2%+2.3%473.0%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue97.07M86.16M79.2M67.64M65.32M
Cost of Revenue00004.59M
Gross Profit97.07M86.16M79.2M67.64M60.74M
Gross Margin100.0%100.0%100.0%100.0%93.0%
Research & Development174.11M164.52M163.52M131.48M106.74M
Selling, General & Admin32.54M45.48M52.89M57.85M43.93M
Operating Expenses206.65M210M216.41M189.33M146.09M
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
EBITDA(104.25M)(119.22M)(123.48M)(104.51M)(70.78M)
EBITDA Margin-107.4%-138.4%-155.9%-154.5%-108.4%
Operating Income(109.57M)(123.84M)(137.21M)(121.69M)(85.35M)
Operating Margin-112.9%-143.7%-173.2%-179.9%-130.7%
Interest Income2.02M1.57M11.36M14.77M9.48M
Interest Expense005.15M10.94M7.68M
Other Income / Expenses1.99M1.66M6.21M3.9M1.8M
Income Before Tax(107.58M)(122.19M)(131M)(117.79M)(83.55M)
Pre-Tax Margin-110.8%-141.8%-165.4%-174.2%-127.9%
Income Tax Expense(28.58M)(433K)2.82M(1.74M)(1.66M)
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (Basic)(3.92)(5.91)(6.38)(5.48)(3.84)
EPS (Diluted)(3.92)(5.91)(6.38)(5.48)(3.84)
Weighted Avg Shares20.17M20.6M20.97M21.16M21.34M
Weighted Avg Shares (Diluted)20.17M20.6M20.97M21.16M21.34M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.